left space About Us Product Candidates Newsroom Investor Information Business Development

IDDS logo

  Javelin is a specialty pharmaceutical company committed to the development of drugs to treat intense, moderate-to-severe pain
Read more
pixel shim

pixel shim
 AMEX :: JAV
pixel shim pixel shim
Quote 2.88
Change 0.00
Date 5/12/2008
Time 4:01pm
Min Delayed Quote
pixel shim

Javelin Pharma's Chinese Microsite

 

 

News:

May 9, 2008
Javelin Pharmaceuticals to Announce First Quarter 2008 Financial Results

May 8, 2008
Javelin Pharmaceuticals, Inc. to Raise $27.6 Million through Registered Direct Offering

April 16, 2008
Javelin Pharmaceuticals Appoints John C. Taylor as Vice President of Business Development

April 1, 2008
Javelin CEO to Present at Fortis Biotechnology Conference in London England

March 14, 2008
Javelin Pharmaceuticals CEO to Present at Cowen & Company's 28th Annual Health Care Conference

March 10, 2008
Javelin Pharmaceuticals' Dyloject Accepted by Scottish Medicines Consortium (SMC)

March 6, 2008
Javelin Pharmaceuticals Reports Results for the Year Ended 2007

March 4, 2008
Javelin Pharmaceuticals Board Appoints Industry Veteran Martin Driscoll as Chief Executive Officer

 

  
 

 

CONTACT US   JOIN US   SITE MAP
© 2005-07 Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.